AVXL

Business Context and Reporting Period

Company: Anavex Life Sciences Corp. (AVXL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008
Status: Development Stage Company (No revenue generated since inception in 2004)
Business Focus: Discovery and development of novel drug targets for cancer (SIGMACEPTOR-C) and neurological diseases (SIGMACEPTOR-N), including Alzheimer's and epilepsy.

Key Financial Metrics

Note: The company reported a cash balance of only $614 at period end. The filing states the company is in default on promissory notes totaling $1,684,500 as of December 31, 2008.

Material Changes vs. Prior Period

• Liquidity Deterioration: Cash on hand decreased from $6,357 (Sept 30, 2008) to $614 (Dec 31, 2008), a reduction of approximately 90%.
• Expense Reduction: Total operating expenses decreased to $906,723 from $989,024 in the prior year quarter. This was driven by a decline in consulting fees ($515,567 vs. $619,368) and legal fees ($3,610 vs. $14,040), partially offset by a significant increase in accounting and audit fees ($31,260 vs. $2,150).
• Debt Position: Promissory notes payable increased from $1,550,000 to $1,684,500. Accounts payable and accrued liabilities increased from $749,389 to $1,073,951.
• Stock Issuances: The company issued shares for consulting services and cash during the quarter, increasing outstanding shares to 19,982,420.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

• Going Concern: Management explicitly states that the company's history of losses and lack of revenue raise substantial doubt about its ability to continue as a going concern. The company expects to incur further losses.
• Funding Requirements: Management estimates an operating cash requirement of $5,180,000 for the twelve-month period ending December 31, 2009. Major costs include R&D ($4.3M) and officer compensation ($400k).
• Financing Strategy: The company has no formal plan to address the funding shortfall but is considering debt financing. Subsequent to the period end, the company renegotiated defaulted notes into convertible loans and closed a private placement raising approximately $200,581.
• Operational Milestones: The company intends to begin clinical phase trials on its most advanced compounds (ANAVEX 2-73 and ANAVEX 1-41) in 2009.

Risks and Contingencies

• Debt Default: As of December 31, 2008, the company was in default on promissory notes. These were subsequently renegotiated into convertible loans.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of the end of the period due to existing weaknesses.
• Regulatory and Development Risk: As a development-stage biotech, there is no assurance that drug candidates will receive regulatory approval or generate revenue. Failure to raise capital could force a cessation of operations.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $200,581 raised in the subsequent private placement against the stated $5.18M annual requirement.
• Debt Conversion Terms: Review the specific terms of the convertible loans issued subsequent to December 31, 2008, including the conversion price ($2.50 per Unit) and potential dilution.
• Related Party Transactions: Scrutinize the $515,567 in consulting fees, a significant portion of which was paid to directors and officers, including stock-based compensation.
• Internal Control Remediation: Assess the timeline and feasibility of remediation for the ineffective disclosure controls and procedures.
• Going Concern Status: Confirm whether the company has secured the necessary financing to meet obligations for the next 12 months to avoid insolvency.